Sabirnetug shows superior selectivity for Aβ oligomers over monomer compared to recombinant lecanemab and aducanumab
Compared to the recombinant Aβ monoclonal antibody therapeutics tested, sabirnetug showed the highest selectivity for AβOs over monomeric Aβ. Sabirnetug's observed high level of selectivity makes it well positioned to target AβOs in MCI/AD tissues and biofluids.
Authors
- Mathias Schenk (ORCID: https://orcid.org/0000-0001-6010-2672)
- Erika N. Cline (ORCID: https://orcid.org/0000-0001-8062-4312)
- Stephan Schilling (ORCID: https://orcid.org/0000-0002-0233-4763)
- Elizabeth A. Johnson (ORCID: https://orcid.org/0000-0002-3914-6600)
- Jasna Jerecic
- Thomas Lavoie
- Martin Kleinschmidt
- Jens‐Ulrich Rahfeld
Institutions
- Fraunhofer Institute for Cell Therapy and Immunology (DE)
- Acumen Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103130
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00